grade
analytical standard
Quality Level
technique(s)
HPLC: suitable, gas chromatography (GC): suitable
application(s)
forensics and toxicology
pharmaceutical (small molecule)
veterinary
format
neat
SMILES string
CCCCOc1ccc(CC(=O)NO)cc1
InChI
1S/C12H17NO3/c1-2-3-8-16-11-6-4-10(5-7-11)9-12(14)13-15/h4-7,15H,2-3,8-9H2,1H3,(H,13,14)
InChI key
MXJWRABVEGLYDG-UHFFFAOYSA-N
General description
Bufexamac is a drug with antipyretic, analgesic and anti-inflammatory properties.
Application
Bufexamac may be used as a reference standard in the determination of bufexamac in pharmaceutical formulations using high-performance liquid chromatography (HPLC).
Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.
Other Notes
Find a digital Reference Material for this product available on our online platform ChemisTwin® for NMR. You can use this digital equivalent on ChemisTwin® for your sample identity confirmation and compound quantification (with digital external standard). An NMR spectrum of this substance can be viewed and an online comparison against your sample can be performed with a few mouseclicks. Learn more here and start your free trial.
存储类别
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Allergic contact dermatitis with spreading over extensive regions due to topical use of 5% bufexamac ointment.
Junko Arikawa et al.
The Journal of dermatology, 31(2), 136-138 (2004-05-27)
Yan Pan et al.
The Australasian journal of dermatology, 53(3), 207-210 (2012-08-14)
In Australia bufexamac is mainly used for pharmacist-initiated local treatment of various dermatoses. The European Medicines Agency's Committee for Medicinal Products for Human Use recently recommended that marketing authorisation for bufexamac-containing preparations be revoked throughout the European Union because of
Yoshiki Seto et al.
Journal of pharmaceutical and biomedical analysis, 55(3), 591-596 (2011-03-25)
The present study aimed to modulate the photoreactivity of bufexamac, with a focus on photostability and phototoxicity, by forming an inclusion complex with sulfobutylether-β-cyclodextrin (SBECD). The photobiochemical properties of bufexamac were evaluated by reactive oxygen species (ROS) assay and using